According to a study conducted at the University of Baltimore and involving 51 patients with multiple myeloma, the current standard of care for determining the extent of disease falls short when compared against another method.
Patients with multiple myeloma were given two types of tests to determine the extent of the cancer in their bodies. The standard of care, which is a radiographic skeletal survey, and the method in question, a low dose whole body CT examination.
What they found was that the total number of lesions detected in these patients with:
Low dose whole body CT: 968
Radiographic skeletal survey: 248
The study authors wrote that since stage decides treatment, as many as 31 of the patients in the study would have been staged at a different stage with low dose whole body CT; notably, 13 would have been upstaged from I to II, nine would have been upstaged from I to III and another nine would have been upstaged from II to III.
Low dose whole body CT was much better than radiographic skeletal survey in detecting lesions in the spine, ribs, sternum and flat bones.
Concerns over the radiation dose may be one reason why the test is not widely accepted in the United States.
Source: Medical News Today
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...